How to evaluate a patient’s response to anti-IgE

S.T. Holgate

ABSTRACT: Omalizumab, an anti-immunoglobulin E antibody, is indicated in the European Union (EU) as add-on therapy for patients with severe persistent allergic asthma whose symptoms persist, despite receiving optimised treatment with high-dose inhaled corticosteroids and a long-acting β2-agonist. In an attempt to further optimise the use of omalizumab, studies have been performed to investigate whether patient selection for omalizumab therapy could be further enhanced.

Analyses of pre-treatment baseline variables have shown there is no reliable way to predict which patients within the label population will achieve a greater response to omalizumab. However, a physician’s overall assessment can easily and reliably identify patients who respond to omalizumab. All patients eligible for omalizumab treatment should receive a 16-week trial and treatment should only be continued if the physician judges that a marked improvement in asthma control has been achieved, as specified in the EU label.

By continuing treatment only in patients who respond to omalizumab therapy, unwarranted drug exposure is minimised, while treatment benefit and cost effectiveness of the therapy are maximised.

KEYWORDS: Allergic asthma, anti-immunoglobulin E, omalizumab

Omalizumab is an anti-immunoglobulin (IgE) antibody and is indicated in the European Union (EU) as add-on therapy for patients with severe persistent allergic asthma whose symptoms persist, despite receiving optimised treatment with high-dose inhaled corticosteroids (ICS) and a long-acting β2-agonist (LABA). It has proven efficacy in moderate-to-severe and severe persistent allergic asthma [1-10], and is indicated for the treatment of a highly targeted population.

In an attempt to further optimise the use of healthcare resources, studies have been performed in order to investigate whether patient selection for omalizumab therapy could be further enhanced [11]. Data from clinical trials have been analysed to investigate if patients who achieve greatest benefits from treatment with omalizumab can be identified based on pre-treatment characteristics [11]. The best method for identifying patients who respond to omalizumab following a course of therapy has also been determined [11].

OVERVIEW OF CLINICAL TRIALS

Post hoc analyses were carried out on five randomised, double-blind, placebo-controlled studies [1, 3, 4-8], including the Investigation of Omalizumab in Severe Asthma Treatment (INNOVATE) trial, and two randomised, controlled open-label studies [2, 9]. In all studies, omalizumab was given as add-on therapy to concomitant asthma treatment and administered subcutaneously every 2 or 4 weeks, according to patients’ pre-treatment body weight and baseline IgE levels by use of a dosing table. All trials were >24 weeks in duration (28 weeks for INNOVATE) and enrolled patients with allergic asthma. Patients enrolled in the INNOVATE study [1] had inadequately controlled severe persistent allergic asthma, despite Global Initiative for Asthma (GINA) 2002 step 4 therapy (high-dose ICS and a LABA, with or without additional controller medication). Of these patients, ~60% were receiving additional controller medication (including maintenance oral corticosteroids (22%), leukotriene modifiers (35%) and theophyllines (27%)), which was optimised prior to the 28-week treatment phase. Overall, 93% of patients (aged ≥12 yrs) across the seven studies met GINA 2002 criteria for severe persistent asthma [10].

PREDICTING RESPONSE

Initial exploratory univariate and multivariate analyses of data from the INNOVATE study were conducted based on eight response measures and...
29 baseline variables (table 1). Those baseline variables that demonstrated a significant interaction with treatment response after univariate analyses of the INNOVATE data were included in the multivariate analyses, which evaluated the predictive value of combinations of baseline variables for each response measure. Baseline total IgE was the only characteristic identified as a consistent predictor of response in the univariate and multivariate analyses, with lower baseline IgE being associated with a smaller treatment benefit. However, this finding was only partially supported after further investigation in exploratory efficacy subgroup analysis of data from the larger pooled population from all seven trials [1–9]. Pooled data from all seven studies was used to obtain sufficient patient numbers over a wide range of IgE levels, and subgroup analysis was conducted within four quartiles based on baseline total IgE (0–75, 76–147, 148–273 and ≥274 IU·mL⁻¹). Outcome variables assessed according to baseline total IgE are shown in table 1.

Pooled analyses showed treatment benefit irrespective of baseline IgE. In the omalizumab-treated patients, the asthma exacerbation rate was reduced across all IgE levels, reaching statistically significant decreases in each of the three upper IgE quartiles (table 2; fig. 1). Severe exacerbation rates decreased across all four quartiles in omalizumab-treated patients, with statistically significant differences in quartiles 1, 3 and 4. Total emergency visit rates were significantly reduced for the three upper IgE quartiles. The proportion of patients with a clinically meaningful Asthma Quality of Life Questionnaire (AQLQ) improvement and forced expiratory volume in one second (FEV1) net benefit favoured omalizumab-treated patients in the three upper IgE quartiles. Significant improvements in physician’s overall assessment (complete control/marked improvement in asthma control) were seen in all IgE quartiles (table 2). A comparison of patients with IgE ≤75 and patients with IgE ≥76 IU·mL⁻¹ produced similar results (table 3).

Exacerbation rates in the control group were similar across all IgE levels (table 2; fig. 1), which demonstrates a medical need irrespective of baseline IgE and also highlights a poor correlation between total IgE and disease severity. As such, baseline patient characteristics do not robustly predict treatment response. Further studies are currently ongoing to investigate the potential predictive value of other biomarkers, including baseline levels of specific IgE (particularly in patients with serum IgE ≤75 IU·mL⁻¹), pharmacogenetics (single nucleotide polymorphisms associated with the high-affinity receptor) and blood markers (IgE-mediated inflammatory pathways).

### EVALUATING RESPONSE

Analyses consisting of four main steps were conducted on efficacy results from the INNOVATE study [1] and the four additional randomised, double-blind, placebo-controlled trials [2, 4–8].

#### Step 1

Step 1 was the identification of an effective and accurate measure of response to omalizumab that could select responders who achieved control in terms of exacerbations.

Six measures of response were assessed (table 4), including a physician’s overall assessment of asthma control, graded in a five-level evaluation: complete control; marked improvement in control; discernible but limited control; no appreciable change; and worsening in control. Responders were defined as

| TABLE 1 | Assessment of pre-treatment baseline measures |
|----------|-----------------------------------------------|
| **Univariate analysis** | Response measures |
| | Number, incidence and rate of clinically significant asthma exacerbations (worsening of asthma requiring systemic corticosteroids) |
| | Number and incidence of severe exacerbations (PEF or FEV₁ <60% of personal best and requiring treatment with systemic corticosteroids) |
| | Asthma-related QoL (patients with >0.5-point increase in total AQLQ score) [12, 13] |
| | Physician’s overall assessment (patients judged to have complete control of asthma or marked improvement) [4] |
| | Lung function (patients with ≥200-mL improvement in FEV₁) [14] |
| **Baseline variables** | Overall AQLQ score; ICS: oral corticosteroids used; GINA clinical features; mould allergy; exacerbations in the previous year; sex; age; weight; height; smoker; IgE; pred FEV₁; duration of asthma; number of positive allergens; qualifying FEV₁ reversibility; in hospital during previous year; ever intubated; emergency room during previous year; doctor during previous year; missed school/work during previous year; nocturnal symptom score; daytime symptom score; total symptom score; morning symptom score; morning PEF; rescue medication use; schedule; time since previous exacerbation |
| **Pooled efficacy subgroup analysis** | Asthma exacerbation rate* |
| | Severe exacerbation rate (PEF or FEV₁ <60% or <50% (study dependent) of personal best and requiring treatment with systemic corticosteroids) |
| | Total emergency visit rate (hospital admissions, emergency room visits and unscheduled doctor visits) |
| | FEV₁ clinically meaningful net benefit (patients with ≥200-mL improvement in FEV₁ minus % patients with a >200-mL worsening) [14] |
| | >0.5-point increase in overall AQLQ score [12, 13] |
| | Physician’s overall assessment (complete control of asthma or marked improvement) [6] |

PEF: peak expiratory flow; FEV₁: forced expiratory volume in one second; QoL: quality of life; AQLQ: Asthma Quality of Life Questionnaire; ICS: inhaled corticosteroids; GINA: Global Initiative for Asthma; Ig: immunoglobulin. *defined as a worsening of asthma requiring systemic corticosteroids in three studies [1, 2, 8] and as worsening of asthma requiring systemic corticosteroids or doubling of ICS doses in three studies [3–7] (~90% of events required systemic corticosteroids). One study [9] defined exacerbations as a worsening of asthma requiring systemic corticosteroids or a doubling of ICS in addition to an emergency room visit or hospitalisation (~94% of exacerbations were treated with systemic corticosteroids). Data taken from [11].
those with marked improvement or complete control. All response measures evaluated (with the exception of FEV\textsubscript{1} improvements) were able to discriminate exacerbation outcome. Responders identified by physician’s overall assessment and AQLQ (response defined as ≥0.5-point improvement) had markedly fewer clinically significant exacerbations than non-responders (table 5). Both measures were able to identify a greater proportion of responders compared with single-item measures while maintaining a similar discrimination for exacerbation outcomes.

A large proportion of omalizumab patients identified as responders according to the broader measures of response were also classed as responders by single-item response measures (FEV\textsubscript{1}, daytime symptoms, nocturnal symptoms and night awakenings). However, responders according to single-item measures were not necessarily identified by other single-item or broader measures of response. Using single item measures to assess response to omalizumab was, therefore, not considered to be appropriate as these would lead to false negative results.

Further examination of the broader measures showed that the physician’s overall assessment was able to discriminate for severe asthma exacerbations; however, according to AQLQ, the severe exacerbation rate was similar in both responders and non-responders. Therefore, the physician’s overall assessment was selected as the best definition of response. Similar data were observed in the pooled population.

### Table 2: Efficacy outcomes in subgroups of patients divided in quartiles according to baseline immunoglobulin (Ig)E in the pooled population

| Outcome measure                  | Baseline IgE subgroup |
|----------------------------------|-----------------------|
|                                  | ≤75 IU mL\textsuperscript{-1} | 76–147 IU mL\textsuperscript{-1} | 148–273 IU mL\textsuperscript{-1} | ≥274 IU mL\textsuperscript{-1} |
|                                  | Omalizumab | Control | Omalizumab | Control | Omalizumab | Control | Omalizumab | Control |
| Patients n                       | 602        | 453     | 659        | 421     | 634        | 444     | 616        | 465     |
| Annualised asthma exacerbation rate |           |         |            |         |            |         |            |         |
| % decrease\textsuperscript{a}    | 13.8       | 1.48    | 0.85       | 1.47    | 0.80       | 1.47    | 0.76       | 1.43    |
| p-value                          | 0.227      | <0.001  | <0.001     | <0.001  | <0.001     | <0.001  | <0.001     | <0.001  |
| Annualised severe exacerbation rate |           |         |            |         |            |         |            |         |
| % decrease\textsuperscript{a}    | 0.09       | 0.22    | 0.07       | 0.11    | 0.07       | 0.20    | 0.05       | 0.17    |
| p-value                          | <0.05      | 0.218   | <0.001     | <0.001  | <0.001     | <0.001  | <0.001     | <0.001  |
| Annualised total emergency visit rate |           |         |            |         |            |         |            |         |
| % decrease\textsuperscript{a}    | 0.44       | 0.64    | 0.32       | 0.60    | 0.35       | 0.89    | 0.33       | 0.55    |
| p-value                          | 0.141      | <0.05   | <0.001     | <0.01   | <0.05      | <0.05   | <0.001     | <0.001  |
| FEV\textsubscript{1} net benefit % |           |         |            |         |            |         |            |         |
| p-value                          | 0.289      | 0.057   | 0.099      | <0.001  | <0.001     | <0.001  | <0.001     | <0.001  |
| AQLQ improvement ≥0.5 points %   |           |         |            |         |            |         |            |         |
| p-value                          | 0.298      | <0.001  | <0.001     | <0.001  | <0.001     | <0.001  | <0.001     | <0.001  |
| Physician’s overall assessment % |           |         |            |         |            |         |            |         |
| p-value                          | <0.05      | <0.001  | <0.001     | <0.001  | <0.001     | <0.001  | <0.001     | <0.001  |

FEV\textsubscript{1}: forced expiratory volume in one second; AQLQ: Asthma Quality of Life Questionnaire. \textsuperscript{a}: in rate in omalizumab patients compared with control. Data taken from [11].

### Figure 1: Annualised asthma exacerbation rates in patients according to baseline immunoglobulin (Ig)E (pooled population). □: omalizumab-treated patients; △: controls. \textsuperscript{#}: annualised; \textsuperscript{*}: p=0.227; ***: p<0.001. Data taken from [11].

**Step 2**

Step 2 consisted of the determination, according to the physician’s overall assessment, of whether responders also
showed improvements across a range of other measures of asthma control.

Patients identified as responders according to the physician’s overall assessment had greater benefits for all clinical outcomes (healthcare utilisation, symptoms, rescue medication use, FEV1 and asthma-related quality of life (QoL)) in both INNOVATE (table 6) and the pooled populations, with marked improvements in asthma control and healthcare utilisation. Physician’s overall assessment was shown to be sensitive to patients’ perceptions of improved QoL, as indicated by the correlation with AQLQ score. Similar data were observed in the pooled population.

**Step 3**

Step 3 was a utility analysis to identify objective clinical measures (including combinations of measures) that could identify responders to the physician’s overall assessment.

**TABLE 3**

| Efficacy outcome | Baseline IgE subgroup | Clinical improvement | Rate | n (%) | Rate | n (%) |
|------------------|-----------------------|----------------------|------|-------|------|-------|
| Omalizumab versus control | <75 IU·mL⁻¹ | >76 IU·mL⁻¹ | | | | |
| Clinically significant exacerbation rate | | | -13.8% | -46.8% | |
| Severe exacerbation rate | | | -59.7% | -55.7% | |
| Total emergency visit rate | | | -31.0% | -48.5% | |
| Physician’s overall assessment | | | 49.3 versus 40.2 | 64.5 versus 38.2 | |
| >0.5 improvement in AQLQ % of responders | | | 58.7 versus 54.2 | 68.4 versus 52.7 | |

AQLQ: Asthma Quality of Life Questionnaire. Data taken from [11, 15].

No single response measure (out of more than 50 tested) or combination of measures had a meaningful level of both sensitivity (proportion of true-positive response that has a positive test result) and specificity (proportion of true-negative response that has a negative test result) for detecting physician’s overall assessment responders.

**Step 4**

Step 4 was a comparison of exacerbation rates in omalizumab-treated patients who were responders according to the physician’s overall assessment and in an omalizumab-treated patient population with total baseline IgE ≥76 IU·mL⁻¹.

Rate ratios (omalizumab/placebo) for exacerbation rates for omalizumab-treated responders and for omalizumab-treated patients with total baseline IgE ≥76 IU·mL⁻¹ were calculated. The reduction in asthma exacerbation rates versus placebo was greater in responders than in the overall omalizumab-treated

**TABLE 4**

| Responder definitions assessed for evaluating response to omalizumab |
|---------------------------------------------------------------|
| Physician’s overall assessment (complete control of asthma or marked improvement)⁶ [4] |
| ≥0.5-point improvement in AQLQ overall score [12, 13] |
| ≥200-mL improvement in FEV₁ [14] |
| ≥1.0-point reduction in daytime symptom score (4-point scale; 0: no symptoms; 4: major discomfort) [6] |
| ≥1.0-point reduction in nocturnal symptom score (4-point scale; 0: no symptoms; 4: major discomfort) [6] |

Reduction ≥1-week⁻¹ and by ≥50% in night awakenings

AQLQ: Asthma Quality of Life Questionnaire; FEV₁: forced expiratory volume in one second. ⁶: five-level evaluation (complete control; marked improvement in control; discernible but limited control; no appreciable change; and worsening in control). Data taken from [11].

**TABLE 5**

| Response measure | Clinically significant exacerbations |
|------------------|-------------------------------------|
| | Responder | Nonresponder |
| | n (%) | Rate | n (%) | Rate |
| Physician’s overall assessment | | | | |
| Complete control or marked improvement | 118 (61) | 0.6 ± 1.31 | 77 | 2.6 ± 6.39 |
| AQLQ ≥0.5 improvement | 124 (61) | 0.8 ± 1.45 | 80 | 1.7 ± 2.90 |
| FEV₁ ≥200 mL improvement | 90 (44) | 1.2 ± 2.39 | 116 | 1.1 ± 2.00 |
| Symptom score ≥1.0 reduction | | | | |
| Daytime | 36 (21) | 0.3 ± 0.83 | 140 | 1.7 ± 4.96 |
| Nocturnal | 32 (18) | 0.4 ± 0.87 | 146 | 1.6 ± 4.87 |
| Night awakenings reduced by ≥1 week⁻¹ and ≥50% | 57 (32) | 0.8 ± 2.13 | 121 | 1.7 ± 5.18 |

Data are presented as mean ± SD, unless otherwise stated. AQLQ: Asthma Quality of Life Questionnaire; FEV₁: forced expiratory volume in one second. Imputed exacerbations resulted in some patients with high exacerbation rates not being included in all analysis populations. Therefore, to enable meaningful direct comparisons, all exacerbation rates are presented without imputation. Clinically significant exacerbations were defined as a worsening of asthma requiring treatment with systemic corticosteroids. Data taken from [11].
population and was observed irrespective of baseline IgE (figs 2a and 2b). These data provide further evidence of the limitations of selecting a subpopulation of patients based on total baseline IgE within the range specified for omalizumab therapy (30–700 IU·mL$^{-1}$).

In summary, the physician’s overall assessment was able to identify responders and discriminate clinically significant and severe exacerbation outcomes and other outcomes in responders versus nonresponders, and was also able to identify a high proportion of patients classified as responders by other measures. In addition, the improvements in clinically significant and severe exacerbation rates were similar in responders irrespective of baseline total IgE.

### TIME TO MAXIMAL THERAPEUTIC BENEFIT

For maximum therapeutic benefit, complete desensitisation of the allergic response is needed. Minimisation of cell-bound, cross-linked IgE/allergen complexes on effector cells is achieved through two mechanisms that occur at different times: 1) binding to circulating free serum IgE rendering it inactive, which occurs within days; and 2) the downregulation of high-affinity cell surface IgE receptor (FcεRI) expression, which takes weeks to months, depending on the effector cell type [16–18]. For example, omalizumab reduces FcεRI levels on circulating basophils by >90% in 7 days, whereas FcεRI expression on mast cells remains stable over the first 7 days and is reduced by 90% at 70 days [17]. Based on cell desensitisation data, a minimum treatment of 12 weeks is needed prior to evaluation of clinical benefit. Data from the INNOVATE study [1] shows a plateau of improvement in asthma symptoms and morning peak expiratory flow around 12–16 weeks (fig. 3), reflecting the downregulation of FcεRI receptors on effectors.

Therefore, the omalizumab EU label states that 16 weeks after commencing therapy patients should be assessed by their physician for treatment effectiveness before further injections are administered. The decision to continue omalizumab therapy should be based on whether a marked improvement in overall asthma control is seen. When implementing a 16-week assessment in clinical practice, the physician should define key treatment goals for each patient, including improvements in symptoms, lung function and use of
medication. Patient expectations of treatment should also be established. Regular medication needs to be continued or, if appropriate, reduced in a logical manner as agreed with the physician. Guidelines and requirements of local health authorities should be adopted.

FUTURE DIRECTIONS

Although the physician’s overall assessment is an effective tool for assessing the response to omalizumab, further research is needed on predicting response. The development of an understanding of the differences in the immunopathology of the airways in omalizumab responder and nonresponder patients, and identification of a biochemical predictor of omalizumab response through examination of biomarkers in sputum and blood may provide clues to potential predictive factors valuable in optimising patient selection for omalizumab therapy.

CONCLUSIONS

When a patient with severe allergic asthma has symptoms that remain uncontrolled despite receiving high-dose inhaled corticosteroids along with a long-acting β2-agonist, a trial of omalizumab is appropriate. Analyses of pre-treatment baseline variables as predictors of response to treatment have shown there is no reliable way to predict which patients within the label population will achieve a good response with omalizumab: all patients eligible for omalizumab treatment, based on their symptoms, should be trialled for 16 weeks and omalizumab treatment should be stopped or continued based on the physician’s assessment of response at this time, as specified in the European Union label.

REFERENCES

1. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309–316.

2. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59: 701–708.

3. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59: 709–717.

4. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184–190.

5. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003; 91: 154–159.

6. Solé M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254–261.

7. Buhl R, Solé M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002; 20: 73–78.

8. Holgate ST, Chuchalin AG, Hébert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34: 632–638.

9. Genentech, Inc. A multicenter, randomized, controlled, open-label study to evaluate the safety of XolairTM in moderate to severe persistent asthma subjects already treated with other therapies (ALTO). http://clinicalstudieresults.gene.com/q2143g.pdf. Date last updated: November 2002. Date last accessed: May 2007.

10. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 302–308.

11. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007; 101: 1483–1492.

12. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiler TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76–83.
13 Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in the disease-specific Quality of Life Questionnaire. *J Clin Epidemiol* 1994; 47: 81–87.

14 Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. *Am Rev Respir Dis* 1991; 144: 1202–1218.

15 Novartis AG, data on file.

16 MacGlashan DW, Bochner BS, Adelman DC, et al. Down-regulation of FcεRI expression on human basophils during *in vivo* treatment of atopic patients with anti-IgE antibody. *J Immunol* 1997; 158: 1438–1445.

17 Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. *J Allergy Clin Immunol* 2004; 113: 297–302.

18 Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell FcεRI expression and function. *J Allergy Clin Immunol* 2004; 114: 527–530.